pharma · Acute Myeloid Leukemia · Relapsed and/or refractory Acute Myeloid Leukemia · KURA
Kura Oncology
Kura Oncology is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker KURA. Primary therapeutic focus areas include Acute Myeloid Leukemia, Relapsed and/or refractory Acute Myeloid Leukem
12730 High Bluff Dr, Suite 400, San Diego, California 92130, US HQ
2014 Founded
313 Employees
Public company Type
KURA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 12730 High Bluff Dr, Suite 400, San Diego, California 92130, US
- Founded
- 2014
- Employees
- 313
- Programs
- 25
- Drugs
- 14
- Patents
- 132
KO-MEN-017
Phase 3 · small molecule · NPM1-m and KMT2A-r Acute Myeloid Leukemia
KO-MEN-017 for NPM1-m and KMT2A-r Acute Myeloid Leukemia is a Phase 3 program (small_molecule) at Kura Oncology with 1 ClinicalTrials.gov record(s).
Internal code KO-MEN-017
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Kura Oncology
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- NPM1-m and KMT2A-r Acute Myeloid Leukemia
- Status
- active
- Trials
- 1